Advances in Vascular Prosthesis in Which Lined with Genetically Modified Endothelial Cells_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

DAI Yi , QIAO Zhengrong , SHI De

Department of Vascular Surgery, The First Affiliated Hospital, Chongqing University of Medical Science， Chongqing 400016, China;

Corresponding author：

Keywords：

Vascular prosthesis; Gene therapy; Endothelial cell

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To discuss the endothelial cell which was modified by exogenous anticoagulant genes contribute to the increase of antithrombosis activity of lined vascular prosthesis and the influence to other physiological functions of endothelial cells.
Methods This summarized paper was made on literature review of recent years.
Results The transfection of genes, including plasminogen activator (tPA, uPA, Urokinase), thrombomoduline (TM) and hirudin, etc, to endothelial cells resulted in not only the increase of antithrombosis activity of local vascular, but also the decrease of endothelial cell function in adherence and proliferation.
Conclusion The increase of antithrombosis activity of lined vascular prosthesis has been done by exogenous genes. However, this technique ought to be studied, intensively.

Citation： DAI Yi,QIAO Zhengrong,SHI De. Advances in Vascular Prosthesis in Which Lined with Genetically Modified Endothelial Cells. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2004, 11(1): 86-88. doi: Copy

1.	Dichek DA, Neville RF, Zwiebel JA, et al. Seeding of intravascular stents with genetically engineered endothelial cells [J]. Circulation, 1989; 80(5)∶1347.
2.	Dichek DA, Anderson J, Kelly AB, et al. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors [J]. Circulation, 1996; 93(2)∶301.
3.	Dichek DA, Nussbaum O, Degen SJ, et al. Enhancement of the fibrinolytic activity of sheep endothelial cells by retroviral vectormediated gene transfer [J]. Blood, 1991; 77(3)∶533.
4.	Ekhterae D, Stanley JC. Retroviral vectormediated transfer and expression of human tissue plasminogen activator gene in human endothelial and vascular smooth muscle cells [J]. J Vasc Surg, 1995; 21(6)∶953.
5.	Wilson JM, Birinyi LK, Salomon RN, et al. Implantation of vascular grafts lined with genetically modified endothelial cells [J]. Science, 1989; 244(4910)∶1344.
6.	Dichek DA, Lee SW, Nguyen NH. Characterization of recombinant plasminogen activator production by primate endothelial cells transduced with retroviral vectors [J]. Blood, 1994; 84(2)∶504.
7.	Falk J, Townsend LE, Vogel LM, et al. Improved adherence of genetically modified endothelial cells to smalldiameter expanded polytetrafluoroethylene grafts in a canine model [J]. J Vasc Surg, 1998; 27(5)∶902.
8.	Kopp CW, Grey ST, Siegel JB, et al. Expression of human thrombomodulin cofactor activity in porcine endothelial cells [J]. Transplantation, 1998; 66(2)∶244.
9.	Waugh JM, Yuksel E, Li J, et al. Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model [J]. Circ Res, 1999; 84(1)∶84.
10.	Waugh JM, LiHawkins J, Yuksel E, et al. Thrombomodulin overexpression to limit neointima formation [J]. Circulation, 2000; 102(3)∶332.
11.	Lundell A, Kelly AB, Anderson J, et al. Reduction in vascular lesion formation by hirudin secreted from retrovirustransduced confluent endothelial cells on vascular grafts in baboons [J]. Circulation, 1999; 100(19)∶2018.
12.	Rade JJ, Cheung M, Miyamoto S, et al. Retroviral vectormediated expression of hirudin by human vascular endothelial cells: implications for the design of retroviral vectors expressing biologically active proteins [J]. Gene Ther, 1999; 6(3)∶385.
13.	Vassalli G, Dichek DA. Gene therapy for arterial thrombosis [J]. Cardiovasc Res, 1997; 35(3)∶459.
14.	Dunn PF, Newman KD, Jones M, et al. Seeding of vascular grafts with genetically modified endothelial cells. Secretion of recombinant TPA results in decreased seeded cell retention in vitro and in vivo [J]. Circulation, 1996; 93(7)∶1439.
15.	Huber TS, Welling TH, Sarkar R, et al. Effects of retroviralmediated tissue plasminogen activator gene transfer and expression on adherence and proliferation of canine endothelial cells seeded onto expanded polytetrafluoroethylene [J]. J Vasc Surg, 1995; 22(6)∶795.
16.	Yu H, Wang Y, Eton D, et al. Dual cell seeding and the use of zymogen tissue plasminogen activator to improve cell retention on polytetrafluoroethylene grafts [J]. J Vasc Surg, 2001; 34(2)∶337.
17.	Kimura H, Sakata Y, Hamada H, et al. In vivo retention of endothelial cells adenovirally transduced with tissuetype plasminogen activator and seeded onto expanded polytetrafluoroethylene [J]. J Vasc Surg, 2000; 32(2)∶353.
18.	Jaklitsch MT, Biro S, Casscells W, et al. Transduced endothelial cells expressing high levels of tissue plasminogen activator have an unaltered phenotype in vitro [J]. J Cell Physiol, 1993; 154(1)∶207.
19.	Baer RP, Whitehill TE, Sarkar R, et al. Retroviralmediated transduction of endothelial cells with the lac Z gene impairs cellular proliferation in vitro and graft endothelialization in vivo [J]. J Vasc Surg, 1996; 24(5)∶892.
20.	Inaba M, Toninelli E, Vanmeter G, et al. Retroviral gene transfer: effects on endothelial cell phenotype [J]. J Surg Res, 1998; 78(1)∶31.
21.	Rafii S, Dias S, Meeus S, et al. Infection of endothelium with E1(-)E4(+), but not E1(-)E4(-), adenovirus gene transfer vectors enhances leukocyte adhesion and migration by modulation of ICAM1, VCAM1, CD34, and chemokine expression [J]. Circ Res, 2001; 88(9)∶903.

1. Dichek DA, Neville RF, Zwiebel JA, et al. Seeding of intravascular stents with genetically engineered endothelial cells [J]. Circulation, 1989; 80(5)∶1347.
2. Dichek DA, Anderson J, Kelly AB, et al. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors [J]. Circulation, 1996; 93(2)∶301.
3. Dichek DA, Nussbaum O, Degen SJ, et al. Enhancement of the fibrinolytic activity of sheep endothelial cells by retroviral vectormediated gene transfer [J]. Blood, 1991; 77(3)∶533.
4. Ekhterae D, Stanley JC. Retroviral vectormediated transfer and expression of human tissue plasminogen activator gene in human endothelial and vascular smooth muscle cells [J]. J Vasc Surg, 1995; 21(6)∶953.
5. Wilson JM, Birinyi LK, Salomon RN, et al. Implantation of vascular grafts lined with genetically modified endothelial cells [J]. Science, 1989; 244(4910)∶1344.
6. Dichek DA, Lee SW, Nguyen NH. Characterization of recombinant plasminogen activator production by primate endothelial cells transduced with retroviral vectors [J]. Blood, 1994; 84(2)∶504.
7. Falk J, Townsend LE, Vogel LM, et al. Improved adherence of genetically modified endothelial cells to smalldiameter expanded polytetrafluoroethylene grafts in a canine model [J]. J Vasc Surg, 1998; 27(5)∶902.
8. Kopp CW, Grey ST, Siegel JB, et al. Expression of human thrombomodulin cofactor activity in porcine endothelial cells [J]. Transplantation, 1998; 66(2)∶244.
9. Waugh JM, Yuksel E, Li J, et al. Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model [J]. Circ Res, 1999; 84(1)∶84.
10. Waugh JM, LiHawkins J, Yuksel E, et al. Thrombomodulin overexpression to limit neointima formation [J]. Circulation, 2000; 102(3)∶332.
11. Lundell A, Kelly AB, Anderson J, et al. Reduction in vascular lesion formation by hirudin secreted from retrovirustransduced confluent endothelial cells on vascular grafts in baboons [J]. Circulation, 1999; 100(19)∶2018.
12. Rade JJ, Cheung M, Miyamoto S, et al. Retroviral vectormediated expression of hirudin by human vascular endothelial cells: implications for the design of retroviral vectors expressing biologically active proteins [J]. Gene Ther, 1999; 6(3)∶385.
13. Vassalli G, Dichek DA. Gene therapy for arterial thrombosis [J]. Cardiovasc Res, 1997; 35(3)∶459.
14. Dunn PF, Newman KD, Jones M, et al. Seeding of vascular grafts with genetically modified endothelial cells. Secretion of recombinant TPA results in decreased seeded cell retention in vitro and in vivo [J]. Circulation, 1996; 93(7)∶1439.
15. Huber TS, Welling TH, Sarkar R, et al. Effects of retroviralmediated tissue plasminogen activator gene transfer and expression on adherence and proliferation of canine endothelial cells seeded onto expanded polytetrafluoroethylene [J]. J Vasc Surg, 1995; 22(6)∶795.
16. Yu H, Wang Y, Eton D, et al. Dual cell seeding and the use of zymogen tissue plasminogen activator to improve cell retention on polytetrafluoroethylene grafts [J]. J Vasc Surg, 2001; 34(2)∶337.
17. Kimura H, Sakata Y, Hamada H, et al. In vivo retention of endothelial cells adenovirally transduced with tissuetype plasminogen activator and seeded onto expanded polytetrafluoroethylene [J]. J Vasc Surg, 2000; 32(2)∶353.
18. Jaklitsch MT, Biro S, Casscells W, et al. Transduced endothelial cells expressing high levels of tissue plasminogen activator have an unaltered phenotype in vitro [J]. J Cell Physiol, 1993; 154(1)∶207.
19. Baer RP, Whitehill TE, Sarkar R, et al. Retroviralmediated transduction of endothelial cells with the lac Z gene impairs cellular proliferation in vitro and graft endothelialization in vivo [J]. J Vasc Surg, 1996; 24(5)∶892.
20. Inaba M, Toninelli E, Vanmeter G, et al. Retroviral gene transfer: effects on endothelial cell phenotype [J]. J Surg Res, 1998; 78(1)∶31.
21. Rafii S, Dias S, Meeus S, et al. Infection of endothelium with E1(-)E4(+), but not E1(-)E4(-), adenovirus gene transfer vectors enhances leukocyte adhesion and migration by modulation of ICAM1, VCAM1, CD34, and chemokine expression [J]. Circ Res, 2001; 88(9)∶903.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Advances in Vascular Prosthesis in Which Lined with Genetically Modified Endothelial Cells

Abstract Full text Figures/Tables Video References Cited by

Format

Content